University of California

Ibogaine By David Dardashti Shares Insight On New Study By Stanford University

Retrieved on: 
Thursday, February 1, 2024

The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.

Key Points: 
  • The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.
  • The University of California has asserted that ibogaine has the ability to increase serotonin levels, which may contribute to the recovery of damaged brain cells.
  • Medicalnewstoday, a leading source of medical news and information, has also reported on the potential of ibogaine in promoting cell recovery.
  • Ibogaine By David Dardashti is proud to be at the forefront of this research and looks forward to further advancements in the field.

Hico Management Launches 'Hico-Bow Joint Fund', Attracting External LPs. Accelerating AI Investments in the Tech Innovation Hub of Silicon Valley

Retrieved on: 
Thursday, February 1, 2024

This was done through a joint fund formed in partnership with Bow Capital, a globally influential venture investment firm.

Key Points: 
  • This was done through a joint fund formed in partnership with Bow Capital, a globally influential venture investment firm.
  • SK Networks (CEO : Hojeong Lee) announced on February 1 that Hico Management and Bow Capital Management formed a joint fund.
  • This joint fund was formed by Hico Management in collaboration with Bow Capital Management.
  • Hico Management is an investment management subsidiary of Hico Capital that leads SK Networks' operation in the U.S.

University of Nebraska, Lincoln Takes Top Honors at 22nd Annual Deloitte FanTAXtic National Case Study Competition

Retrieved on: 
Tuesday, January 30, 2024

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- A team of students from University of Nebraska, Lincoln, claimed victory at the Deloitte FanTAXtic national case study competition by presenting the best analysis on a complex, issues-driven business tax case. This year's case challenged teams to provide advice on how to structure a new business entity and help determine whether they should operate the venture as an S corporation or a C corporation. Teams were also asked to share advice on tax issues like how to calculate depreciation, when to recognize income, and how to calculate a specific business income deduction. The national finals were held Jan. 19-21 at Deloitte University, Deloitte's landmark campus for learning and leadership development in Westlake, Texas.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- A team of students from University of Nebraska, Lincoln, claimed victory at the Deloitte FanTAXtic national case study competition by presenting the best analysis on a complex, issues-driven business tax case.
  • The national finals were held Jan. 19-21 at Deloitte University, Deloitte's landmark campus for learning and leadership development in Westlake, Texas.
  • The other teams that participated were: Florida International University; San Diego State University; University at Albany; University of California, Los Angeles; University of Cincinnati; University of Florida; University of Houston; University of Illinois, Urbana – Champaign; University of Massachusetts; University of Mississippi; University of Southern California; University of Tennessee; and University of Utah.
  • Each of the 16 teams participating in the national competition won the Deloitte FanTAXtic contest in their respective U.S. regions.

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Retrieved on: 
Wednesday, January 17, 2024

The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).

Key Points: 
  • The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).
  • “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.
  • AMPLIFY-7P is a Phase 1 and Phase 2 study of ELI-002 7P in patients with RAS mutated pancreatic and colorectal tumors after locoregional treatment.
  • A Phase 2 interim analysis is planned using group sequential design for control of overall alpha 0.10.

More Employers Board Clipper® BayPass, Provide Workers Unlimited Free Transit

Retrieved on: 
Tuesday, January 23, 2024

SAN FRANCISCO, Jan. 23, 2024 /PRNewswire/ -- The Metropolitan Transportation Commission (MTC) this month finalized agreements with the Alameda Transportation Management Association (Alameda TMA) and City of Menlo Park to provide up to a combined 1,900 people with passes for unlimited free travel for one year on any of 24 Bay Area transit agencies. The agreements with the two entities are part of Phase 2 of the Clipper® BayPass program, which is jointly managed by MTC and BART. 

Key Points: 
  • More than 1,700 total participants from more than two dozen member organizations are eligible to participate in Clipper BayPass.
  • MTC teamed with BART and other transit agencies to launch Phase I of the Clipper BayPass pilot in August 2022.
  • Fare coordination and integration is a cornerstone of the Bay Area Transit Transformation Action Plan adopted by MTC in 2021.
  • Transit agencies later in 2024 will expand fare integration with the launch of a pilot program for no-cost and reduced-cost transfers between agencies.

Supportive, Stable Caregiving in Childhood Protects Heart Health in Adulthood

Retrieved on: 
Tuesday, January 23, 2024

New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.

Key Points: 
  • New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.
  • "At the same time, our findings show that adversity in early childhood does not equal destiny.
  • While adverse childhood family environments were associated with lower odds of cardiovascular health in adulthood, our findings suggest that supportive and, importantly, stable caregiving may have a stronger influence on later heart health than early adversity."
  • The hope, says Ortiz, is that this study offers insight into how supporting healthy, both supportive and stable, caregiving relationships in childhood can offer greater attainment of CVH at a population level.

Dr. Rana Baroudi Celebrates One Year as Associate Clinical Professor of Periodontology at UCSF

Retrieved on: 
Tuesday, January 16, 2024

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- The University of California, San Francisco (UCSF) School of Dentistry is proud to celebrate Dr. Rana Baroudi's first year as an Associate Clinical Professor of Periodontology. Dr. Baroudi has brought a wealth of experience, expertise, and innovation to the department, significantly enhancing both our academic and clinical offerings.

Key Points: 
  • The University of California, San Francisco (UCSF) School of Dentistry is proud to celebrate Dr. Rana Baroudi's first year as an Associate Clinical Professor of Periodontology.
  • SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- The University of California, San Francisco (UCSF) School of Dentistry is proud to celebrate Dr. Rana Baroudi's first year as an Associate Clinical Professor of Periodontology.
  • Dr. Baroudi has brought a wealth of experience, expertise, and innovation to the department, significantly enhancing both our academic and clinical offerings.
  • As we celebrate this milestone, UCSF looks forward to Dr. Baroudi's ongoing contributions and leadership in the field of periodontology.

Atossa Therapeutics Issues Letter to Shareholders

Retrieved on: 
Tuesday, January 9, 2024

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:

Key Points: 
  • SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:
    2023 marked another year of significant progress for Atossa.
  • If you would like to learn more about the study, please visit www.atossatherapeutics.com to view a short video interview I conducted with Dr.
  • Adding to the issue is the fact that there are currently no approved treatments to reduce breast density.
  • On behalf of the board of directors, management, and employees of Atossa Therapeutics, we thank you for your investment and continued support of our Company.

Renowned UCLA Business School Professor, Olav Sorenson, Tapped to Launch and Chair the Academic Advisory Board for Breakout Learning

Retrieved on: 
Tuesday, January 9, 2024

In addition to recruiting top academics to author the case studies, Sorenson will lead the board’s entrepreneurship practice.

Key Points: 
  • In addition to recruiting top academics to author the case studies, Sorenson will lead the board’s entrepreneurship practice.
  • More than 2,000 students used the platform in the fall of 2023 at top business schools, including the NYU Stern School of Business, the Carroll School of Management at Boston College and the UCLA Anderson School of Management.
  • More than 90% of these students reported that they prefer the Breakout Learning case-study method compared to traditional case studies.
  • To date, authors have been recruited from Yale School of Management, the Wharton School of the University of Pennsylvania, Dartmouth College’s Tuck School of Business and the NYU Stern School of Business.

Medical Education Market size to grow by USD 208.73 billion from 2022 to 2027, Market is fragmented due to the presence of prominent companies like All India Institute of Medical Sciences, KP Bernard J. Tyson School of Medicine and Mayo Clinic, and many m

Retrieved on: 
Friday, January 5, 2024

The medical education market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The medical education market is fragmented owing to the presence of many global and regional companies.
  • Download a Sample before buying
    KP Bernard J. Tyson School of Medicine - The company offers medical education such as a Bachelor of Science (BS) in Health Sciences.
  • National University of Singapore - The company offers medical education such as M.D.M.B.A., M.D.Ph.D., M.D.M.P.H., and M.D.MSHCM, and others.
  • The higher education testing and assessment market is estimated to grow at a CAGR of 6.32% between 2022 and 2027.